SGL Investment Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.14M Buy
923
+125
+16% +$128K 0.39% 55
2026
Q1
$772K Buy
798
+14
+2% +$14.2K 0.29% 69
2025
Q4
$800K Sell
784
-88
-10% -$84.1K 0.32% 71
2025
Q3
$782K Buy
872
+434
+99% +$323K 0.33% 64
2025
Q2
$341K Buy
438
+39
+10% +$30.3K 0.16% 98
2025
Q1
$300K Buy
399
+94
+31% +$78.2K 0.15% 94
2024
Q4
$266K Buy
305
+33
+12% +$27.3K 0.13% 94
2024
Q3
$214K Buy
+272
New +$245K 0.11% 100

Other funds holding LLY

SGL Investment Advisors's LLY Position: Q2 2026 in Review

SGL Investment Advisors increased its Eli Lilly (LLY) stake by 16% in Q2 2026, buying an estimated $128K and bringing the position to 923 shares worth $1.14M. The position accounts for 0.39% of the portfolio, ranked #55.

SGL Investment Advisors first reported a position in LLY in Q3 2024 and has held it in 8 quarters since. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • SGL Investment Advisors held 923 shares of Eli Lilly worth $1.14M as of Q2 2026.
  • SGL Investment Advisors bought 125 Eli Lilly shares in Q2 2026, an estimated $128K.
  • Eli Lilly made up 0.39% of SGL Investment Advisors's portfolio in Q2 2026, its #55 holding.
  • SGL Investment Advisors first reported a position in Eli Lilly in Q3 2024 and has held it in 8 quarters since.
  • 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on SGL Investment Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.